The second imaging agent will be 99m Tc-EC-annexin V. A clinical pilot study has been completed and an IND application for a combination Phase I/II clinical trial study has been submitted to the FDA. The Phase I/II  study, in addition to safety, will assess tumor apoptosis (programmed cell death) in patients with primary breast cancer and detect and image treatment related apoptosis in patients with primary breast cancer. Additional indications will be studied in Phase III.  It is expected that by using 99mTc-EC-annexin V, the radiation oncologist will be able to detect cell death much sooner than current practice. Assessment of tumor apoptosis will be useful to evaluate the efficacy and mechanisms of therapy and disease progression or regression.